Reata Pharmaceuticals Announces First Patient Enrolled in Phase 1 Trial of RTA 408 in Non-Small Cell Lung Cancer and Melanoma
IRVING, Texas, January 15, 2014 – Reata Pharmaceuticals, Inc., announced enrollment of the first patient in the Phase 1 trial of RTA 408 in patients with advanced, refractory metastatic non-small cell lung cancer (NSCLC) and melanoma.
RTA 408 is a novel oleanane triterpenoid that through activation of Nrf2 and inhibition of NF-κB suppresses tumor-driven inflammation that masks cancers from the immune system. Myeloid-derived suppressor cells (MDSCs) produce large amounts of reactive oxygen (ROS) and nitrogen species (RNS) in the tumor micro-environment. ROS and RNS act as a molecular “cloak” that prevents killer T-cells from recognizing tumors. Preclinical data show that RTA 408 and analogs reduce tumor ROS and RNS levels, inhibit the activity of MDSCs, augment T-cell anticancer activity, and restore immune recognition of tumor-specific antigens, thereby enhancing the capacity of the immune system to mount an antitumor response.
Lung cancer is the most common cause of cancer mortality for men and women, with NSCLC accounting for approximately 85% of all lung cancers. The National Cancer Institute (NCI) estimates that there will be more than 150,000 deaths from lung cancer in the United States in 2014. Metastatic melanoma is a leading cause of death from cutaneous malignancies, accounting for about three-fourths of all skin cancer deaths. The five-year survival rate for patients with metastatic melanoma is approximately 16%.
The first-in-human study is evaluating the safety, tolerability, pharmacodynamic activity, and efficacy of RTA 408 when administered to patients with metastatic NSCLC or melanoma who have failed available treatment options. The Phase 1, open-label, single-center, dose-escalation study began enrolling patients at the H. Lee Moffitt Cancer Center in Tampa, Florida. Additional sites are being activated and will contribute to the anticipated enrollment of approximately 40 patients. For more information on this study, visit: http://clinicaltrials.gov/show/NCT02029729.
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc. is a privately held company aiming to translate innovative research into breakthrough medicines for difficult diseases that have significant unmet needs. Reata is the leader in developing a novel class of drugs with potent transcription-regulating activity called antioxidant inflammation modulators (AIMs). AIMs activate Nrf2, promoting the production of numerous antioxidant, detoxification, and anti-inflammatory genes, and inhibit NF-κB, a transcription factor that regulates many pro-inflammatory proteins. The pharmacology of the AIMs mimics that of endogenous prostaglandin metabolites that are responsible for the orchestrated resolution of inflammation. The anti-inflammatory, cytoprotective and energy metabolism effects of AIM pharmacology have been documented in more than 250 scientific papers and are potentially relevant to a wide range of diseases.
Reata Pharmaceuticals, Inc.